Helix integrates genomic data into healthcare systems, enabling health organizations to utilize population genomics for personalized diagnosis, treatment, and prevention. By providing actionable genetic insights, Helix enhances patient outcomes and reduces costs across medical research and clinical care.
Funding
$435M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current healthcare systems often struggle to integrate and utilize the vast amounts of available genomic data for personalized patient care. This lack of integration hinders the ability of healthcare organizations to leverage population genomics for improved diagnosis, treatment, and preventative measures.
Solution
Helix provides a platform that enables health organizations and life science companies to integrate genomic data into their workflows, facilitating the use of population genomics for personalized healthcare. The platform offers solutions for health systems to establish sustainable, enterprise-wide growth by making genomics accessible and actionable. Helix's integrated genomics solutions provide insights that accelerate R&D, reduce costs, and improve outcomes for life sciences companies. The company's end-to-end platform supports various applications, including disease risk identification, proactive health management, and viral surveillance, enabling a more personalized and effective approach to healthcare.
Target Audience
Helix serves health systems seeking to improve patient outcomes and reduce costs, life sciences companies aiming to accelerate drug discovery and development, and public health organizations focused on disease surveillance and prevention.
Features
- End-to-end genomics platform for integrating genomic data into clinical care and research
- Population genomics programs to identify individuals at risk for diseases based on inherited genetic mutations
- Viral surveillance capabilities for tracking respiratory viral variants
- Proprietary Exome+® assay for high-quality data at population scale
- Sequence Once, Query Often™ model for running future tests without additional sample collection
- CLIA/CAP-accredited next-generation sequencing lab
- Secure data storage and handling practices